<DOC>
	<DOCNO>NCT00671996</DOCNO>
	<brief_summary>The present feasibility study design find whether pre-treatment compound mangafodipir lower frequency severity side effect adjuvant chemotherapy accord FOLFOX6 regimen patient operate upon colon cancer stage Dukes ' C .</brief_summary>
	<brief_title>Mangafodipir Adjunct FOLFOX6 Chemotherapy Colon Cancer Stage Dukes ' C</brief_title>
	<detailed_description>Mangafodipir , manganese ( Mn ) dipyridoxyl diphosphate , catalytic antioxidant iron chelator recently ( 2006 ) suggest cancer treatment Editorial Journal National Cancer Institute . Preclinical research show mangafodipir protects normal tissue without loss anti-tumour activity chemotherapy . Other advantage mangafodipir already approve use patient contrast agent magnetic resonance imaging ( MRI ) liver , experience decade reveals high safety mainly minor tolerable side-effects . The present study include 14 patient follow throughout 3 treatment cycle . Each cycle precede infusion mangafodipir placebo two group , consist 7 patient . The primary endpoint frequent manifestation FOLFOX6 , namely neutropenia neurosensory toxicity . The secondary endpoint frequency severity FOLFOX6-related adverse event quality life .</detailed_description>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Edetic Acid</mesh_term>
	<mesh_term>Pyridoxal Phosphate</mesh_term>
	<criteria>1 . Histologically proven colon cancer stage Dukes ' C. 2 . Patient 18 year . 3. WHO performance status &lt; 1 . 4 . Adequate haematological function ( Hb ≥ 100 g/L , ANC ≥ 2.0 x 109/L , platelet ≥ 150 x 109/L ) 5 . Adequate renal hepatic function : serum creatinine total bilirubin ≤ 1.25 time upper normal limit ( ASAT ALAT ≤ 3 time upper normal limit ) 6 . Clinical evaluation , haematology biochemistry perform within 1 week prior start chemotherapy 7 . Use adequate contraception ( male reproductive potential ) 8 . Written informed consent give 1 . Other tumour type colon adenocarcinomas 2 . Current severe neutropenia , leucopenia thrombocytopenia 3 . Severely reduced liver renal function 4 . Unresolved bowel obstruction subobstruction , uncontrolled Crohn 's disease ulcerative colitis 5 . Current chronic diarrhoea 6 . Contraindication corticosteroid administration 7 . History prior serious allergic pseudoallergic reaction 8 . Any serious illness medical condition 9 . Symptomatic peripheral neuropathy ≥ grade 2 10 . Received mangafodipir ≤ 5 week plan start chemotherapy 11 . Received FOLFOX drug ≤ 5 week plan start chemotherapy 12 . Any plan administer anticancer therapy ( include radiotherapy ) concurrent study 13 . Fertile females 14 . Males reproductive potential implementing adequate contraception measure 15 . Phaeochromocytoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>